Publication date: Jul 17, 2025
Our study demonstrates that IVIG lots manufactured in 2023-2024 contain neutralizing antibodies against circulating Omicron variants, including KP. 3 and XEC. These variants are resistant to all convalescent plasma and IVIG preparations produced prior to 2023. Therefore, recent IVIG lots may provide some protection against COVID-19 caused by circulating SARS-CoV-2 variants.
Open Access PDF
| Concepts | Keywords |
|---|---|
| Basel | antibody therapy |
| Convalescent | convalescent plasma |
| Immunoglobulins | COVID-19 |
| Plasma | immunoglobulins |
| SARS-CoV-2 | |
| treatment | |
| variants |
Semantics
| Type | Source | Name |
|---|---|---|
| drug | DRUGBANK | Immune Globulin Human |
| disease | MESH | COVID-19 |
| drug | DRUGBANK | Silver |
| disease | MESH | morbidity |
| disease | IDO | immunodeficiency |
| disease | MESH | syndromes |
| disease | MESH | infectious diseases |
| disease | IDO | blood |
| disease | MESH | infections |
| disease | IDO | history |
| drug | DRUGBANK | Ethanol |
| disease | IDO | infection |
| disease | MESH | breakthrough infections |
| disease | IDO | assay |
| drug | DRUGBANK | Aspartame |
Original Article
(Visited 1 times, 1 visits today)